Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Accepts healthy volunteers

Incentives for Influenza Vaccination

NCT06300242
Conditions
Influenza Vaccination
Interventions
Reminders, Financial Incentive, Placebo
Behavioral · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
69,972 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Martinez, California
Completed Phase 2 Interventional Accepts healthy volunteers Results available

CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

NCT00943488
Conditions
Influenza
Interventions
Inactivated H1N1 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Iowa City, Iowa • Cincinnati, Ohio • Seattle, Washington
Conditions
Influenza Vaccination
Interventions
Text Messages
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
7,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Influenza, Human
Interventions
FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3, AS03B, AS03A, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
833 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
8
States / cities
Stockbridge, Georgia • Meridian, Idaho • Cary, North Carolina + 5 more
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Optimizing Lymphatic Pumping for Influenza Vaccine Responses in Vulnerable Populations

NCT07786467
Conditions
No Disease or Condition is Being Directly Studied, The Focus of the Study in Healthy Volunteers
Interventions
Osteopathic manipulation, Sham
Other
Lead sponsor
Lake Erie College of Osteopathic Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Erie, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers

H5N1 Vaccination With and Without AS03: Systems Biology Analysis

NCT01573312
Conditions
Influenza
Interventions
ASO3 Adjuvant, Influenza A/H5N1 Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Not applicable Interventional

Impact of Rapid Flu Testing in BMC ED

NCT02979730
Conditions
Influenza-Like Illness, Influenza
Interventions
Core Lab Test, ED Point of Care Test
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Influenza
Interventions
Fluarix™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
3,054 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
9
States / cities
Mobile, Alabama • Delray Beach, Florida • Pembroke Pines, Florida + 6 more
Conditions
Refractory and/or Relapsed Metastatic Solid Tumors
Interventions
Cyclophosphamide, Fludarabine, low dose total body irradiation, Melphalan, Tacrolimus
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
1 Year to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
3
States / cities
Baltimore, Maryland • The Bronx, New York • Valhalla, New York
Conditions
COVID -19, Influenza A, Influenza B, Respiratory Synctial Virus, RSV, Rhinovirus
Interventions
Aptitude Medical Systems Respiratory Panel Test
Diagnostic Test
Lead sponsor
Aptitude Medical Systems
Industry
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Trussville, Alabama
Conditions
Influenza, Human
Interventions
Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005, VRC-AViDNA036-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 4 Interventional Accepts healthy volunteers

Influenza Immunity Against Pandemic Respiratory Virus

NCT00138281
Conditions
Influenza
Interventions
FluMist, Fluzone
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
1
States / cities
Stanford, California
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine

NCT00258830
Conditions
Influenza
Interventions
Fluzone®: Influenza Virus Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Norfolk, Virginia
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

NCT05091307
Conditions
COVID-19 Prevention
Interventions
Ad26.COV2.S, Placebo, Influenza Vaccine
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
861 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
17
States / cities
Tempe, Arizona • San Diego, California • Coral Gables, Florida + 12 more
Conditions
Influenza
Interventions
TCAD, Zanamivir or Oseltamivir, Open label treatment with TCAD
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Conditions
Influenza, Vaccination
Interventions
Messaging, Incentive
Behavioral
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
18 Years and older
Enrollment
22,584 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Conditions
Influenza Infection
Interventions
VAX102 [Flagellin.HuM2e], Placebo
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Lenexa, Kansas • Galveston, Texas
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
17
States / cities
Alabaster, Alabama • Tucson, Arizona • Fountain Valley, California + 14 more
Enrolling by invitation Not applicable Interventional

Patient-Centered Practical Vaccine Talk For Busy Clinicians

NCT07651761
Conditions
Influenza, COVID-19
Interventions
Provider communication training
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
24,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Worcester, Massachusetts
Completed Phase 2 Interventional Accepts healthy volunteers

Half-Dose Flu Vaccine Study in Healthy Adults

NCT00006146
Conditions
Influenza
Interventions
Approved influenza virus vaccine.
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
840 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000
U.S. locations
6
States / cities
Torrance, California • College Park, Maryland • St Louis, Missouri + 3 more
Conditions
Influenza A
Interventions
MHAA4549A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
38
States / cities
Athens, Alabama • Costa Mesa, California • Fountain Valley, California + 32 more
Conditions
Influenza Vaccination
Interventions
Fact Only Education Message, Fact and Myth Educational Message, Fact, Myth, Why Educational Message, Control Educational Message
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
50 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Seasonal Influenza Preventative Vaccine Pharmacodynamics
Interventions
VXA-A1.1 H1 Tablet Vaccine (small), VXA-A1.1 H1 Tablet Vaccine (large)
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Influenza
Interventions
Baloxavir Marboxil, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 64 Years
Enrollment
4,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
43
States / cities
Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 32 more